The American Diabetes Association (ADA) 84th Scientific Sessions took place in Orlando, Florida from 21–24 June, offering a wealth of updates and new data in diabetes and related specialties. The touchENDOCRINOLOGY team monitored the event on X to track the trending topics under #ADA2024. Here are our highlights:

The FLOW trial

There was much excitement around results of the FLOW trial (NCT03819153), the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, which showed that semaglutide significantly reduces the risk of major kidney disease events and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. The results presented on Monday 24 June were simultaneously published in Nature Medicine. 

Tirzepatide shows promising results in sleep apnoea treatment

There was significant discussion on X regarding the findings from the SURMOUNT-OSA study (NCT05412004) on tirzepatide in patients with obstructive sleep apnoea and obesity, which revealed notable improvements in both sleep apnoea severity and related metabolic issues. The results were simultaneously published in the NEJM. 

Founding of the Obesity Association

On the opening day, there was significant support on X for the announcement of the Obesity Association, marking an exciting new era for the organization. In addition to advancing diabetes treatments, the ADA has been pivotal in funding and supporting groundbreaking obesity therapy research. With many innovative new drug therapies for obesity presented at this year’s meeting, the formation of the Obesity Association seems like a timely and promising initiative.

Phase II studies on dual GLP-1 receptor agonists

Considerable attention on X was given to HRS953, a dual GLP-1/GIP receptor agonist, for its effectiveness in reducing body weight, blood pressure, blood glucose, and triglycerides, while maintaining a favourable safety profile. The full abstract is available here. 

Another highlight on X was the promising results of the MOMENTUM trial of pemvidutide, a GLP-1/glucagon dual receptor agonist in development for obesity and MASH to help people overweight and with obesity lose weight. Results showed significantly reducing body weight and serum lipids over 48 weeks of treatment. In addition, body composition analysis demonstrated class-leading preservation of lean mass. Read the full abstract here. 

Wear Red Day

There were plenty of attendees posting their support for ‘Wear Red Day’ on June 23 to show support of the ADA and mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

There were numerous fascinating presentations and data shared at this year’s meeting. Check out the ADA meeting news to learn more about the proceedings.

Disclosures: This article was created by the touchENDOCRINOLOGY team utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No funding was received in the publication of this article.

Looking for more content on diabetes? Take a look at our latest articles, conference coverage and education here.